Compare Cardinal Health Inc (CAH) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Schwab US Large Cap Growth ETF — how do they compare? Cardinal Health Inc trades at $228.59 (market cap $53.89B), while Schwab US Large Cap Growth ETF trades at $34.73. The key difference: Cardinal Health Inc pays a 0.89% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals.
| CAH | SCHG | |
|---|---|---|
Market Cap | $53.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $239.71 | $35.30 |
52-Week Low | $146.04 | $28.10 |
Enterprise Value | $58.87B | — |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.37, down 0.81% on the day. The technical outlook is bullish with moving averages signaling strength, while oscillators are neutral. Recent news highlights its concentrated exposure to AI-driven tech giants like Nvidia, Apple, and Microsoft, positioning it for potential growth from AI capital expenditure trends. The fund's portfolio carries a P/E around 32x, reflecting premium valuations amid moderate 2026 performance.
Outlook: SCHG offers leveraged growth potential through top tech holdings but faces risks from high concentration and interest rate sensitivity. Upside hinges on AI adoption, while downside could stem from tech sector volatility or economic shifts. Institutional inflows suggest confidence, yet investors must weigh valuation against diversification limits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
